Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

Table 4 Comparison of the incidence of major drug-related adverse events between groups at the final follow-up

Adverse events	CAP-B (n = 130)	CAP (n = 133)	P-value
Haematological and non-haematological events	18(13.8%)	9(6.9%)	0.059^a
Peripheral sensory neuropathy	21(16.2%)	15(11.3%)	0.250^a
Myocardial ischaemia	11(8.5%)	6(4.5%)	0.193^a
4-grade diarrhoea	14(10.8%)	4(3.0%)	0.013*^a

^*Statistically significant values. ^aAnalysed using the Chi-square test. CAP-B capecitabine plus bevacizumab, CAP capecitabine

ISSN: 1471-230X